Plus Therapeutics Inc.

Contributing Author

Recent Articles by Plus Therapeutics Inc.

Jun-25	Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET PSTV +68.45% GlobeNewswire
Jun-25	Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer PSTV +68.45% GlobeNewswire
Jun-24	Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing PSTV GlobeNewswire
May-30	Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights PSTV GlobeNewswire
May-23	Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q PSTV GlobeNewswire
May-14	Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) PSTV GlobeNewswire
May-08	Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference PSTV GlobeNewswire